Intensity Therapeutics (INTS) Cash from Operations (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Cash from Operations came in at 1826000.0 in Q1 2026, up 8.2% YoY from 1687692.38 in Q1 2025, and up 23.95% on a QoQ basis from 2401000.0 in Q4 2025.
Intensity Therapeutics (INTS) Cash from Operations (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Cash from Operations data on file, last reported at 1826000.0 in Q1 2026.
- Quarterly Cash from Operations rose 8.2% year-over-year to 1826000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9070000.0 (up 29.38% YoY) and the FY2025 annual result came in at 9233000.0, up 39.34% from the prior year.
- Cash from Operations advanced to 1826000.0 in Q1 2026, from 2401000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 239000.0 in Q2 2023 to a low of 5119000.0 in Q3 2023.
- A 5-year average of 2409600.67 and a median of 2387000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations tumbled 1663.18% — and 2025, when it jumped 54.44%.
- Tracing INTS's Cash from Operations over 5 years: stood at 1634337.0 in 2022, then surged by 42.12% to 946000.0 in 2023, then plunged by 182.03% to 2668000.0 in 2024, then gained by 10.01% to 2401000.0 in 2025, then advanced by 23.95% to 1826000.0 in 2026.
- The last three Cash from Operations figures came in at 1826000.0 (Q1 2026), 2401000.0 (Q4 2025), and 2387000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | -2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.34 Mn |
| Jun 30, 2026 | -2.34 Mn |
| Mar 31, 2026 | -1.83 Mn |
| Mar 31, 2026 | -1.83 Mn |
| Dec 31, 2025 | -2.40 Mn |
| Dec 31, 2025 | -2.40 Mn |
| Sep 30, 2025 | -2.39 Mn |
| Sep 30, 2025 | -2.39 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.67 Mn |
| Dec 31, 2024 | -2.67 Mn |
| Sep 30, 2024 | -3.97 Mn |
| Sep 30, 2024 | -3.97 Mn |
| Jun 30, 2024 | -4.21 Mn |
| Jun 30, 2024 | -4.21 Mn |
| Mar 31, 2024 | -4.37 Mn |
| Mar 31, 2024 | -4.37 Mn |